Ardelyx (ARDX) Share-based Compensation (2013 - 2026)
Ardelyx (ARDX) reported Share-based Compensation of $14.2 million for Q1 2026, up 17.12% on a YoY basis from $12.1 million in Q1 2025, and up 13.76% quarter-over-quarter from $12.4 million in Q4 2025.
Ardelyx (ARDX) Share-based Compensation (2013 - 2026) Analysis & Trends
Ardelyx has reported Share-based Compensation for 14 years, with the latest figure at $14.2 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 17.12% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $51.0 million (up 21.93% YoY), and the FY2025 full-year result was $49.0 million, up 30.98% from the prior year.
- Share-based Compensation for Q1 2026 stood at $14.2 million, up from $12.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $14.2 million in Q1 2026, with the low at $1.8 million in Q3 2022.
- Historically, Share-based Compensation has averaged $7.3 million across 5 years, with a median of $7.6 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 44.51% — and 2024, when it surged 236.64%.
- Ardelyx's Share-based Compensation stood at $1.9 million in 2022, then soared by 104.05% to $3.9 million in 2023, then jumped by 150.97% to $9.9 million in 2024, then increased by 26.18% to $12.4 million in 2025, then grew by 13.76% to $14.2 million in 2026.
- The last three Share-based Compensation figures came in at $14.2 million (Q1 2026), $12.4 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 14.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.16 Mn |
| Mar 31, 2026 | 14.16 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Sep 30, 2025 | 12.74 Mn |
| Sep 30, 2025 | 12.74 Mn |
| Jun 30, 2025 | 11.69 Mn |
| Jun 30, 2025 | 11.69 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Dec 31, 2024 | 9.86 Mn |
| Dec 31, 2024 | 9.86 Mn |
| Sep 30, 2024 | 9.13 Mn |
| Sep 30, 2024 | 9.13 Mn |
| Jun 30, 2024 | 10.77 Mn |
| Jun 30, 2024 | 10.77 Mn |
| Mar 31, 2024 | 7.62 Mn |
| Mar 31, 2024 | 7.62 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Dec 31, 2023 | 3.93 Mn |